Research Assistant Professor
UH College of Pharmacy
Texas Medical Center Campus
1441 Moursund Street
Houston, TX 77030
Bachelor of Science (B.S.) Chemistry, 1996, University of North Carolina, Chapel Hill, North Carolina
HIV/AIDS, pharmacokinetics (PK)/pharmacodynamics (PD) of HIV drugs, pharmacogenetic correlations with PK/PD of HIV drugs, drug distribution and metabolism in special populations (women, minorities), drug interactions with HIV drugs
Yeh RF, Pawlikowski MA, Blough DK, McDonald GB, O'Donnell PV, Rezvani A, Deeg HJ, McCune JS. Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2012 Feb;18(2):265-72.
Yeh RF, Lipman BA, Mayberry C, Miguel B, Nemecek JJ, Gathe JC Jr. Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults. J Int Assoc Physicians AIDS Care (Chic). 2010 Sep-Oct;9(5):273-7.
Palmer HR, Cottreau JM, Garey KW, Hirsch EB, Musick WL, Tam VH, Yeh RF; Houston Infectious Diseases Network. Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm. 2010 Aug;67(15):e34-42. Review.
Birtcher KK, Corbett SM, Pass SE, Coyle EA, Yeh RF, Tipton J, Garey KW. Symposium on roles of and cooperation between academic- and practice-based pharmacy clinicians. Am J Health Syst Pharm. 2010 Feb 1;67(3):231-8.
Yeh RF, Jain R, Palmer HR. 49th ICAAC annual meeting: optimization of anti-infective use in the clinical setting. Expert Rev Anti Infect Ther. 2009 Dec;7(10):1167-72.
Yeh RF, Rezk NL, Kashuba ADM, Dumond JB, Tappouni HL, Chen Y, Vourvahis M, Boggess KA, Horton AL, Fiscus SA, Patterson KB. Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs During and After Pregnancy in HIV-1 Infected Women. Antimicrob Agents Chemother 2009;53(6):2367-74.
Sansgiry SS, Ajouga E, Ngo C, Yeh RF. Impact of Over-the-Counter Medication Misuse and Adverse Drug Events on HIV Patients Health-Related Quality of Life. J Pharm Technol 2008;24:323-9.
Yeh RF, Kuper KM, Coyle EA, Garey KW, Ikwuagwu JO, Maclayton DO, Mohr JF, Musick WL, Pass SE, Rios E, Tam VH. Significant Papers on Infectious Diseases Pharmacotherapy in 2007. Am J Health Syst Pharm 2008;65:e72-79.
Ajouga E, Sansgiry SS, Ngo C, Yeh RF. Use/Misuse of Over-the-Counter Medications in HIV-infected Patients and Associated Adverse Drug Events in Social and Administrative Pharmacy. Res Social Adm Pharm 2008;4(3):292-301.
Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, Bridges AS, Stewart PW, Cohen MS, Kashuba AD. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007 Sep 12;21(14):1899-907.
Tam VH, Kabbara S, Yeh RF, Leary RH. Impact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob Agents Chemother. 2006 Nov;50(11):3950-2.
Rezk NL, Crutchley RD, Yeh RF, Kashuba AD. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit. 2006 Aug;28(4):517-25.
Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006 May;42(1):52-60.
Yeh RF, Wattal R, Sansgiry SS, Sudharshan L, Yost S, Mayberry C, Ceperley M, Rahim S, Joseph C. Gathe Jr. JC. Predictors of Effectiveness with Lopinavir/Ritonavir (LPV/r) Single Agent Therapy (SAT) to Improve Clinical Outcomes in High Risk HIV+ Patients in an Urban Clinic. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress. Paris, France. Oct 24-27, 2009. Abstract PIN3.
Gathe Jr. JC, Yeh RF, Mayberry C, Nemecek J, Miguel B, Lipman BA, Fath MJ, Norton M. Single Agent Therapy with Lopinavir/Ritonavir Durably Suppresses Viral Replication in ARV naïve patients: IMANI II – 96 Week Final Results. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Infectious Diseases Society of America (IDSA), Washington, D.C. Oct 25-28, 2008.
Wattal R, Yeh RF, Sansgiry SS. Role of drug distribution strategies to improve health outcome in high risk patients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting. Toronto, Canada. May 3-7, 2008. Abstract PIN39.
Ajuoga E, Yeh RF, Wattal R, Gathe Jr. JC, Sansgiry SS. Complementary and alternative medications (CAM) use and adverse events in HIV-infected patients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting. Toronto, Canada. May 3-7, 2008. Abstract PIN41.
Yeh RF, Ajuoga E, Hou J, Prince RA, Wattal R, Vinh T, Gathe Jr. JC, Sansgiry SS. Lack of pharmacokinetic interaction of ritonavir-boosted lopinavir and atazanavir with cranberry juice in HIV-positive individuals. 9th International Workshop on the Clinical Pharmacology of HIV Therapy. New Orleans, LA. April 7-9, 2008. Abstract P28.
Gupta SA, Yeh RF, Sansgiry SS. Effect of drug distribution on antiretroviral adherence in a low-income metropolitan HIV+/AIDS population. XVI International AIDS Conference, Toronto, Canada. August 2006. Abstract CDB0756.
Tam VH, Kabbara S, Yeh RF, Leary RH. Impact of sample size on the performance of multiple model stochastic simulations. 16th European Congress of Clinical Microbiology and Infectious Diseases. Nice, France, April 1-4, 2006. Abstract O-353.
Dumond J, Yeh R, Patterson K, Corbett A, Jung B, Rezk N, Bridges A, Dempsey E, Cohen M, Kashuba ADM. First Dose and Steady-State (SS) Genital Tract (GT) Pharmacokinetics (PK) of Ten Antiretroviral Drugs in HIV-Infected Women: Implications for Pre- (PREP) and Post- (PEP) Exposure Prophylaxis. 13th Conference of Retroviruses and Opportunistic Infections, Denver, CO. February 5-8, 2006. Abstract T-119, Oral Presentation.
Yeh R, Gaver V, Park J, Patterson K, Rezk N, Baxter-Meheux F, White N, Klein C, Rublein J, Eron, Jr. J, Kashuba ADM. Lopinavir/ritonavir Inhibits Intestinal to a Greater Extent than Hepatic CYP3A Activity, Using Midazolam as a Biomarker in Healthy Human Volunteers. 6th International Workshop of Clinical Pharmacology in HIV Therapy, Quebec, Canada. April 28-30, 2005. Abstract 8, Oral Presentation.
Most Influential Literature on HIV/AIDS and Opportunistic Infections, 2008-2009. Most Influential Publications in Infectious Diseases Pharmacotherapy, 2008-2009 (ACPE-accredited CME Workshop), 49th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA. September 2009.
The Impact of Complementary and Alternative Medicine Use on Antiretroviral Plasma Concentrations and Adherence. Unique Challenges in Managing HAART in HIV Positive Patients session (ACPE-accredited CME), American Society of Health-Systems Pharmacists (ASHP) 2008 Midyear Clinical Meeting and Exhibition, Orlando, FL. December 2008.
New Classes, New Drugs, New Questions. St. Luke’s Episcopal Hospital, Department of Infectious Diseases, Grand Rounds, Houston, TX. March 2008
Academic Fellowships and Providing Outpatient Clinical Care in HIV. University of Houston, Student Society of Health-Systems Pharmacists (SSHP), Houston, TX. March 2008.
Chemokine Coreceptor Antagonists in the Treatment of HIV Infection. Texas Children’s Hospital, Allergy and Immunology Department, Houston, TX. July 2007.
Integrase Inhibitors for Treatment of Highly Antiretroviral-Experienced HIV Infection. Texas Children’s Hospital, Allergy and Immunology Department, Houston, TX. July 2007.
HIV Update 2007. Houston Infectious Diseases Pharmacotherapists Network, Houston, TX. May 2007.
Single Agent Therapy with Lopinavir/Ritonavir Controls HIV-1 Replication in the Central Nervous System. The Methodist Hospital Research Institute New Investigator Symposium, Houston, TX. April 2007.
Clinical Pharmacology of Antiretrovirals. Center for AIDS Research Seminar, Baylor College of Medicine/University of Texas- Houston, Houston, TX. March 2007.
Medication Cabinet Safety- “Keep it or Toss it”. 5-minute live television segment, KHOU Channel 11, "Great Day Houston," Houston, TX. February 2007.
Antiretroviral Toxicities in Pediatrics and Adolescents. In service presentation to nurse practitioners, physicians, pharmacy students, Texas Children’s Hospital, Houston, TX. January 2007.
Alcohol and Drug Interactions. 3-minute television interview, KPRC Channel 2 Morning Show, Houston, TX. December 2006.
Medication Safety. 10-minute live television interview, KHOU Channel 11, "Great Day Houston," Houston, TX. July 2006
Antiretroviral Drugs in HIV Treatment of Pediatrics and Adolescents. In service presentation to nurse practitioners, Texas Children’s Hospital, Houston, TX. June 2006, November 2006, December 2006.
Update on HIV Treatment and Drug Interactions, Continuing Education Seminar and Conference, Texas Society of Health-Systems Pharmacists 58th Annual Seminar & Alcade XX Conference, Galveston, TX. March 2006
Update on the Treatment of HIV Infection, Infectious Diseases Symposium, University of Houston, Houston, TX. May 2005
Lopinavir/ritonavir Inhibits Intestinal to a Greater Extent than Hepatic CYP3A Activity, Using Midazolam as a Biomarker in Healthy Human Volunteers. 6th International Workshop of Clinical Pharmacology in HIV Therapy, Quebec City, Canada; Platform Presentation. April 2005
- 2006- present, American Journal of Pharmaceutical Education Reviewer
- 2006, University of Houston Associated Students of Pharmacy/American Pharmaceutical Society of Health-Systems Pharmacists Residency Panel
- 2006-2007, Society of Infectious Diseases Pharmacists, Internet/Website Committee
- 2005, American Society of Health-Systems Pharmacists, Pharmacokinetics/Pharmacodynamics Network expert panel
- 2006- present, American Society for Microbiology
- 2006- present, American Association of Colleges of Pharmacy
- 2005- present, American Society for Clinical Pharmacology and Therapeutics
- 2003- present, Society of Infectious Disease Pharmacists
- 2002- present, Society of Critical Care Medicine
- 2001- present, American College of Clinical Pharmacy
- 1999- present, American Society of Health-System Pharmacists
- 1998- present, Kappa Psi Professional Pharmacy Fraternity